# Absorption & Elimination of Radiolabelled GSK2269557

> **NCT03315559** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** [14C]-GSK2269557 IV infusion
- **DRUG:** GSK2269557 via DPI
- **DRUG:** [14C]-GSK2269557 oral solution

## Key facts

- **NCT ID:** NCT03315559
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315559, "Absorption & Elimination of Radiolabelled GSK2269557". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03315559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*